"Death occurred about three months and a half after the onsetof the acute disease and the lung was two thirds of the normalsize, grayish in color, and hard as cartilage. Microscopicallythese areas showed advanced fibrotic changes and great thickeningof the alveolar walls." Thus did Sir William Osler describe,in 1892, a case of idiopathic pulmonary fibrosis1 — anunrelenting and progressive disease that afflicts more than5 million patients worldwide. The number of patients who receivethis diagnosis has doubled within the past decade, and yet thereis no effective treatment. The overall prognosis is dismal,. . . [Full Text of this Article]
Source Information
From the Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and the University of Toronto — all in Toronto.
This article has been cited by other articles:
Germano, D., Blyszczuk, P., Valaperti, A., Kania, G., Dirnhofer, S., Landmesser, U., Luscher, T. F., Hunziker, L., Zulewski, H., Eriksson, U.
(2009). Prominin-1/CD133+ Lung Epithelial Progenitors Protect from Bleomycin-induced Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med.
179: 939-949
[Abstract][Full Text]
Hardie, W. D., Davidson, C., Ikegami, M., Leikauf, G. D., Le Cras, T. D., Prestridge, A., Whitsett, J. A., Korfhagen, T. R.
(2008). EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-{alpha}-induced pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol.
294: L1217-L1225
[Abstract][Full Text]
Kim, H. P., Choi, A. M. K.
(2008). Caveolin-1 stops profibrogenic signaling?. Am. J. Physiol. Lung Cell. Mol. Physiol.
294: L841-L842
[Full Text]
Previous
